☆ 4.7 Editorial Material

Extinguishing the fire in sickle cell anemia

BLOOD (2022)

Related references

Note: Only part of the references are listed.

Article Hematology

A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia

David C. Rees et al.

Summary: This study found that selective IL-1 beta blockade by canakinumab in patients with sickle cell anemia can reduce inflammation markers, clinical events, and hospitalizations, with potential improvements in symptoms such as pain intensity.

BLOOD (2022)

Add to Collection

Review Hematology

What is the future of patient-reported outcomes in sickle-cell disease?

Sharon A. Singh et al.

EXPERT REVIEW OF HEMATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

A Phase 3 Trial of L-Glutamine in Sickle Cell Disease

Yutaka Niihara et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

K. I. Ataga et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

P. M. Ridker et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Neuroinflammation: the devil is in the details

Damon J. DiSabato et al.

JOURNAL OF NEUROCHEMISTRY (2016)

Add to Collection

Article Medicine, General & Internal

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events

Matthew M. Heeney et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.